| |
INDICATIONS AND
CONSIDERATIONS |
TECHNIQUE |
| NON-INVASIVE
DISEASE GUIDELINES |
| DCIS |
After
breast conserving surgery, margins clear
Margins
<3mm wider excision recommended prior to adjuvant RT |
Two-field
tangential beams
- 4250 cGy in 16 fractions or 5000
cGy in 25 fractions
- or partial breast treatment
(one week) as per OCOG study
- Margins of >3mm are recommended (deep margin is an exception
if went to fascia)
- Boost can be applied
if patient declines re-excision |
|
INVASIVE
DISEASE GUIDELINES |
| SEGMENTAL
RESECTION
Lymph Node Negative |
All patients recommended radiotherapy
following segmental resection |
Tangential
breast fields
- 4250 cGy in 16 fractions
- 5000 cGy in 25 fractions
- 4500 cGy in 20 fractions
Or partial breast treatment
(one week) as per OCOG study (for tumors < 3cm) |
| SEGMENTAL RESECTION Lymph Node
Positive |
1-3
positive nodes |
For
both pre- and post-menopausal patients, regional nodal radiation
is not recommended. Results from MA-20 will clarify whether nodal
radiation is of benefit in this group. |
| |
|
|
| |
Any number of nodes resected
with 4 or more positive; pre- or post menopausal |
-
Radiation to breast and regional nodes, including IMC's:
- 5000 cGy in 25
fractions
- 4500 cGy in 20
fractions
- If > 10 nodes resected,
may exclude axilla and treat IMC/supraclavicular area only |
| MASTECTOMY |
-
tumor > 5 cm
- skin involvement
- muscle involvement |
Radiation
to chest wall and regional lymph nodes, including the IMC's
- 5000 cGy in 25 fractions
- 4500 cGy in 20 fractions |
| |
- 1-3 nodes positive |
All
patients to be referred for radiation oncologist consultation:
Pre-menopausal-regional
node radiation in this setting is individualized.
Post-menopausal - If tamoxifen
only used, regional nodal radiation, including IMC's, is recommended.
When chemotherapy is used, regional nodal radiation in this setting
is individualized.
- 4500 cGy in 20 fractions
- 5000 cGy in 25 fractions
Addendum: The data from
the Danish update for pre-menopausal, 1-3+ nodes shows a survival
benefit when CMF chemotherapy was given. There is no survival data
from the Danish study in post-menopausal, 1-3+ nodes treated with
chemotherapy as they were all treated with Tamoxifen. The absolute
benefit of locoregional radiotherapy, in reduction of locoregional
recurrence, is in the range of 5%. |
| |
|
|
| |
Any
number of nodes resected with 4 or more positive; pre- or post-menopausal
|
Chest
wall and regional nodal radiotherapy, including IMC's:
- 5000 cGy in 25 fractions
- 4500 cGy in 20 fractions
If > 10 nodes resected,
may exclude axilla and treat IMC/supraclavicular area only |
|
MARGINS
NOT CLEAR - INVASIVE AND NON-INVASIVE DISEASE |
Breast
conserving surgery:
RADIATION BOOST |
Primary
recommendation:
further surgery to clear margins |
If
wider excision not an option
- 1000 cGy in 4 or 5 fractions
if whole breast treated to 4250 cGy in 16 fractions
- Recommend 1000 cGys
in 5 fractions or 1600 cGys in 8 fractions when 5000 cGys in 25
fractions used or 4500 cGy in 25 fractions (as an option in large
breasted patients)
- Boost recommended to
be sequential to tangent treatments
- All women under age
40 recommended to have boost even if clear margins
- Over age 40 boost for
<3 mm margins at the discretion of RO
For post-mastectomy patients,
no radiation recommended if margins close or focally positive. If
grossly positive resection margin, there may be benefit from chest
wall radiaiton. (Tamoxifen should also be considered (ER status
may help decide which patient benefits) if patient had DCIS only).
Bolus is recommended if radiation is delivered to chest wall. Details
of bolus are at radiation oncologist's discretion. |